Sign inJoin waitlistJoin the waitlist

Ronac Mamtani

Associate Professor in GU Oncology · Perelman School of Medicine at the University of Pennsylvania

Credentials: · · ·

History

Perelman School of Medicine at the University of Pennsylvania
Present

University of Pennsylvania Health System
2009–2011
NewYork-Presbyterian
2006–2009
Stony Brook University School of Medicine
2002–2006

Research

Fecal microbiota transplant promotes response in immunotherapy-refractory melanoma patients
Science · 2021 · 1,371 citations
Progressive multifocal leukoencephalopathy after rituximab therapy in HIV-negative patients: a report of 57 cases from the Research on Adverse Drug Events and Reports project
Blood · 2009 · 694 citations
Pembrolizumab alone or combined with chemotherapy versus chemotherapy as first-line therapy for advanced urothelial carcinoma (KEYNOTE-361): a randomised, open-label, phase 3 trial
The Lancet Oncology · 2021 · 549 citations

Yu-Xiao Yang
40 papers
James Lewis
29 papers
Frank Scott
23 papers
Ravi Parikh
22 papers · 17 as a fellow
BG
Bruce Giantonio
16 papers
Kim Reiss-Binder
16 papers
David Vaughn
13 papers
EB
Erin Bange
13 papers · 11 as a fellow
Cary Gross
10 papers · 5 as a resident
LS
Lova Sun
10 papers · 7 as a fellow
RC
Roger Cohen
10 papers
Giorgos Karakousis
9 papers

Grants

Insulin Resistance in the Development and Progression of Invasive Bladder Cancer
National Cancer Institute · K23
Contact PI · $872K · University of Pennsylvania
2015–2020

Clinical trials

Text-based Intervention to Minimize the Time Burden of Routine Cancer Care
Principal investigator · Completed
Abramson Cancer Center at Penn Medicine
2021–2022
Combining Immunotherapy and Radiation Therapy to Help Patients Avoid Bladder Removal After Treatment Shrinks Muscle Invasive Bladder Cancer, BRIGHT Trial
Site PI · Recruiting · Phase 2
National Cancer Institute (NCI)
2025–2027
Testing the Addition of MEDI4736 (Durvalumab) to Chemotherapy Before Surgery for Patients With High-Grade Upper Urinary Tract Cancer
Site PI · Recruiting · Phase 2, Phase 3
National Cancer Institute (NCI)
2021–2027